Nov 9, 2020 ProMIS Neurosciences offers comments on recent FDA Advisory Committee meeting on aducanumab for the treatment of Alzheimer’s disease
Oct 23, 2020 ProMIS Neurosciences Announces Up to $3 Million Private Placement Offering of Special Warrants
Oct 21, 2020 ProMIS Neurosciences Offers its Perspective on the Likelihood of Regulatory Approval of Aducanumab
Oct 13, 2020 ProMIS Neurosciences’ Neil Cashman to Speak at Protein Misfolding Drug Discovery Conference